Literature DB >> 1373705

Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature.

D Schmitter1, B Lauber, B Fagg, R A Stahel.   

Abstract

Seven mesothelioma cell lines, established from patients with pleural mesothelioma, exhibited substantial heterogeneity regarding in vitro morphology and growth characteristics. Media conditioned by these cell lines and by MeT5A normal mesothelial cells were examined for (i) colony formation on human bone-marrow cells, (ii) hematopoietic growth-factor content and (iii) mitogenic activity on mesothelioma cells. Colony-stimulating activity was produced only by the ZL34 cell line. Analysis of conditioned media by ELISA revealed that all mesothelioma cell lines constitutively produced IL-6, while the MeT5A normal mesothelial cells did not; in addition, GM-CSF and G-CSF were detected in the supernatant of the ZL34 cell line. Using a 3H-thymidine incorporation assay, we showed that all mesothelioma cell lines produced mitogenic activity in the culture supernatant, in contrast to the MeT5A normal mesothelial cells. The mitogenic effect of the hematopoietic growth factors detected in mesothelioma culture supernatants was tested on mesothelioma cells and on MeT5A normal mesothelial cells: IL-6, GM-CSF and G-CSF did not stimulate any DNA synthesis. Our results suggest that these hematopoietic growth factors do not act as autocrine growth factors. A common feature of this panel of mesothelioma cell lines is the production of IL-6; although the biological significance of the aberrant production of cytokines by mesotheliomas remains unclear, IL-6 might be involved in paraneoplastic syndromes such as thrombocytosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373705     DOI: 10.1002/ijc.2910510220

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

1.  Inflammation in malignant mesothelioma - friend or foe?

Authors:  Anthony Linton; Nico van Zandwijk; Glen Reid; Stephen Clarke; Christopher Cao; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

2.  Evidence for a common mutation in hereditary pancreatitis.

Authors:  S M Bell; C Bennett; A F Markham; N J Lench
Journal:  Mol Pathol       Date:  1998-04

3.  Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.

Authors:  Zhiwen Liu; Julius Klominek
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

4.  Spatio-temporally precise activation of engineered receptor tyrosine kinases by light.

Authors:  Michael Grusch; Karin Schelch; Robert Riedler; Eva Reichhart; Christopher Differ; Walter Berger; Álvaro Inglés-Prieto; Harald Janovjak
Journal:  EMBO J       Date:  2014-07-01       Impact factor: 11.598

Review 5.  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Authors:  J W Upham; M J Garlepp; A W Musk; B W Robinson
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

6.  Biological noise and positional effects influence cell stemness.

Authors:  Walter Blum; Thomas Henzi; Beat Schwaller; László Pecze
Journal:  J Biol Chem       Date:  2018-02-12       Impact factor: 5.157

7.  Utilization of gene profiling and proteomics to determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1).

Authors:  Jedd M Hillegass; Arti Shukla; Maximilian B MacPherson; Jeffrey P Bond; Chad Steele; Brooke T Mossman
Journal:  J Toxicol Environ Health A       Date:  2010

8.  Absence of HHV-8 DNA sequences in malignant mesothelioma.

Authors:  V Ascoli; F Nardi; C Carnovale Scalzo; S Signoretti; A Pistilli; F Lo Coco
Journal:  Mol Pathol       Date:  1998-04

9.  Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.

Authors:  H Bielefeldt-Ohmann; A L Marzo; R P Himbeck; A G Jarnicki; B W Robinson; D R Fitzpatrick
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

10.  Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction.

Authors:  J Klominek; B Baskin; D Hauzenberger
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.